Report results from the Phase 2 proof-of-concept study of VX-864 in Z-AAT deficiency
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 29 Apr 2021
- Due
- 30 Jun 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Patients enrolled in the Phase 2 proof-of-concept study for the Z-AAT corrector, VX-864, have completed the 28-day dosing period... results are expected in the second quarter of 2021.”
What we found
Evidence strength A What the grades mean
A 10-Q filed July 2021 says Vertex announced in June 2021 that the Phase 2 VX-864 study met its primary endpoint, within the Q2 2021 window.
-
A Vertex Pharmaceuticals 10-Q filed 2021-07-30
“In June, we announced that we had achieved our primary endpoint and established proof of mechanism in a Phase 2 clinical trial evaluating our Z-AAT corrector, VX-864.” ✓ confirmed on the page
-
A Vertex Pharmaceuticals 10-K filed 2022-02-09
“in June 2021, we announced that we had achieved our primary endpoint and established proof of mechanism in a Phase 2 clinical trial evaluating our Z-AAT corrector, VX-864.” ✓ confirmed on the page
Market reaction: the shares moved -0.3% against the S&P 500 over the three sessions around the disclosure (29 Jul 2021 to 3 Aug 2021). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- VX-864 Phase 2 proof-of-concept study results
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Vertex Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-VRTX-006491 · Corrections policy